Compare Freeport-McMoRan Inc (FCX) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Freeport-McMoRan Inc vs Travere Therapeutics Inc. Common Stock — how do they compare? Freeport-McMoRan Inc trades at $68.86 (market cap $104.00B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Freeport-McMoRan Inc is far larger — about 21.3× Travere Therapeutics Inc. Common Stock's market cap, and Freeport-McMoRan Inc pays a 0.83% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Freeport-McMoRan Inc for 70 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| FCX | TVTX | |
|---|---|---|
Market Cap | $104.00B | $4.88B |
Volume | 7,316,762 | 1,668,577 |
Sector | Basic Materials | Health |
52-Week High | $79.91 | $67.52 |
52-Week Low | $38.65 | $26.79 |
Typical Hold Time | 70 Days | 0 Days |
Enterprise Value | $110.28B | $5.01B |
Dividend Yield | 0.83% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FCX trades at $69.62, down 5.01% today, but maintains strong technical momentum with bullish moving averages. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 results pending. Copper demand fundamentals remain robust, driven by AI infrastructure needs, while FCX's expansion projects position it for growth. Analyst consensus remains strongly bullish with a $73.27 price target.
FCX presents a compelling investment case with strong copper demand tailwinds and consistent earnings outperformance. However, rising production costs and a high P/E ratio of 35.5 warrant caution. The stock offers exposure to copper's structural deficit while carrying execution risks from expansion projects and commodity price volatility.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Freeport-McMoRan Inc
Freeport-McMoRan Inc is an international mining company. It operates geographically diverse assets with proven and probable mineral reserves of copper, gold and molybdenum. The company's portfolio of assets includes the Grasberg minerals district in Indonesia
Read more on FCX →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
